TNFRSF1B and acute myeloid leukemia: Our data indicate that the frequency of TNFR2 expression on PB CD4+ T cells could become a novel and easily accessible marker, which can be used to predict clinical outcomes or monitor the progress of AML patients subjected to standard cytotoxic therapy.